These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 9222076

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
    Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, Friedman HL.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():75-80. PubMed ID: 9222074
    [Abstract] [Full Text] [Related]

  • 3. Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.
    Vincent J, Dogolo L, Baris BA, Willavize SA, Teng R.
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):427-30. PubMed ID: 9758287
    [Abstract] [Full Text] [Related]

  • 4. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.
    Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():93-7. PubMed ID: 9222077
    [Abstract] [Full Text] [Related]

  • 5. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.
    Cutler NR, Vincent J, Jhee SS, Teng R, Wardle T, Lucas G, Dogolo LC, Sramek JJ.
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1298-300. PubMed ID: 9174187
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.
    Teng R, Girard D, Gootz TD, Foulds G, Liston TE.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):561-6. PubMed ID: 8851571
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension.
    Shah A, Liu MC, Vaughan D, Heller AH.
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():49-54. PubMed ID: 10225572
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
    Bradley JS, Kearns GL, Reed MD, Capparelli EV, Vincent J.
    Antimicrob Agents Chemother; 2000 May; 44(5):1195-9. PubMed ID: 10770751
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
    Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE.
    J Antimicrob Chemother; 1995 Aug; 36(2):385-94. PubMed ID: 8522468
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
    Vincent J, Teng R, Dalvie DK, Friedman HL.
    Am J Surg; 1998 Dec; 176(6A Suppl):8S-13S. PubMed ID: 9935250
    [Abstract] [Full Text] [Related]

  • 20. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.
    Teng R, Liston TE, Harris SC.
    J Antimicrob Chemother; 1996 May; 37(5):955-63. PubMed ID: 8737145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.